Volume | 3,379 |
|
|||||
News | - | ||||||
Day High | 4.09 | Low High |
|||||
Day Low | 3.81 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Xenetic Biosciences Inc | XBIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.09 | 3.81 | 4.09 | 3.8955 | 4.0417 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
45 | 3,379 | $ 3.95 | $ 13,354 | - | 2.55 - 5.97 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 194 | $ 3.8955 | USD |
Xenetic Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.01M | 1.54M | - | 2.54M | -4.14M | -2.68 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Xenetic Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XBIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.85 | 4.27 | 3.81 | 4.02 | 4,573 | 0.0455 | 1.18% |
1 Month | 4.46 | 4.46 | 3.74 | 4.03 | 3,602 | -0.5645 | -12.66% |
3 Months | 3.79 | 4.74 | 3.55 | 4.19 | 5,736 | 0.1055 | 2.78% |
6 Months | 2.93 | 4.74 | 2.8696 | 3.88 | 5,405 | 0.9655 | 32.95% |
1 Year | 4.20 | 5.97 | 2.55 | 3.60 | 16,012 | -0.3045 | -7.25% |
3 Years | 18.40 | 56.80 | 2.401 | 29.42 | 939,928 | -14.50 | -78.83% |
5 Years | 13.10 | 168.895 | 2.401 | 26.51 | 745,235 | -9.20 | -70.26% |
Xenetic Biosciences Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. |